Pharmatizing AI: Insights from Frontiers Health 2025

Digital

Artificial intelligence is reshaping pharma, but what does it mean to truly pharmatize AI? At Frontiers Health 2025, we capturedoff-stage conversations with Renzo DiCarlo (AstraZeneca) and James Kugler (EMD Digital), following a dynamic panel moderated by Roberto Ascione and featuring perspectives from Monique Levy, Diana Nanova, and Luca Quagliata.

This discussion explores:

How AI is accelerating drug development and clinical trials
Why trust and transparency are critical for scaling AI responsibly
The convergence of life sciences, technology, and pharma in shaping the future

From synthetic patient populations to data lineage and competitive advantage, the conversation offers a clear view of the opportunities and challenges ahead for AI in healthcare.

Watch the full interview and discover how AI is being pharmatized to deliver smarter, faster, and more reliable innovation.

Jonah Comstock

19 November, 2025

Pharmatizing AI

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.